Lytic efficiency of immunosuppressive drug-resistant armoured T cells against circulating HBV-related HCC in whole blood [0.03%]
免疫抑制药物耐药性盔甲T细胞在全血中对抗HBV相关循环肝癌细胞的裂解效率研究
Meiyin Lin,Sebastian Chakrit Bhakdi,Damien Tan et al.
Meiyin Lin et al.
Recurrence of hepatitis B virus-related hepatocellular carcinoma (HBV-HCC) after liver transplant (LT) is mediated by circulating tumour cells (CTCs) and exacerbated by the immunosuppressants required to prevent graft rejection. To circumve...
Combination therapies for the optimisation of Bispecific T-cell Engagers in cancer treatment [0.03%]
双特异性T细胞衔接器癌症治疗的联合疗法优化
Winston M Zhu,Mark R Middleton
Winston M Zhu
Bispecific T-cell engagers (BiTEs) redirect endogenous T-cell populations to cells expressing tumour-associated antigens to induce tumour cell killing. This inherently relies upon a cytotoxic T-cell population that is able to be recruited. ...
Challenges in tolerogenic dendritic cell therapy for autoimmune diseases: the route of administration [0.03%]
自身免疫性疾病耐受性树突状细胞治疗的挑战：给药途径的影响
María José Mansilla,Catharien M U Hilkens,Eva M Martínez-Cáceres
María José Mansilla
Tolerogenic dendritic cells (tolDCs) are a promising strategy to treat autoimmune diseases since they have the potential to re-educate and modulate pathological immune responses in an antigen-specific manner and, therefore, have minimal adv...
Establishing a single-sex controlled human Schistosoma mansoni infection model for Uganda: protocol for safety and dose-finding trial [0.03%]
建立乌干达单性别的人类曼氏血吸虫感染模型：安全性和剂量寻优试验方案
Andrew Abaasa,Moses Egesa,Emmanuella Driciru et al.
Andrew Abaasa et al.
Control of schistosomiasis depends on a single drug, praziquantel, with variable cure rates, high reinfection rates, and risk of drug resistance. A vaccine could transform schistosomiasis control. Preclinical data show that vaccine developm...
Correction to: Advancement of antigen-specific immunotherapy: knowledge transfer between allergy and autoimmunity [0.03%]
特刊：过敏和自身免疫之间知识转移推动特异性免疫疗法进步的评论
[This corrects the article DOI: 10.1093/immadv/ltab009.]. © The Author(s) 2023. Published by Oxford University Press on behalf of the British Society fo...
Published Erratum
Immunotherapy advances. 2023 Jul 27;3(1):ltad004. DOI:10.1093/immadv/ltad004 2023
Blockade of innate inflammatory cytokines TNF α, IL-1 β, or IL-6 overcomes virotherapy-induced cancer equilibrium to promote tumor regression [0.03%]
阻断天然炎症因子TNFα、IL-1β或IL-6可克服病毒疗法引起的肿瘤平衡以促进肿瘤消退
Michael J Walsh,Lestat R Ali,Patrick Lenehan et al.
Michael J Walsh et al.
Cancer therapeutics can lead to immune equilibrium in which the immune response controls tumor cell expansion without fully eliminating the cancer. The factors involved in this equilibrium remain incompletely understood, especially those th...
Leveraging the lymphohematopoietic graft-versus-host reaction (LGVHR) to achieve allograft tolerance and restore self tolerance with minimal toxicity [0.03%]
利用淋巴血细胞移植物抗宿主反应(LGVHR)实现同种异体移植耐受并最小限度毒性地恢复自身耐受性
Megan Sykes
Megan Sykes
Mixed allogeneic chimerism has considerable potential to advance the achievement of immune tolerance to alloantigens for transplantation and the restoration of self-tolerance in patients with autoimmune disease. In this article, I review ev...
Treg-based immunotherapy for antigen-specific immune suppression and stable tolerance induction: a perspective [0.03%]
基于Treg的免疫治疗在抗原特异性免疫抑制和耐受诱导中的作用：展望
Shimon Sakaguchi,Ryoji Kawakami,Norihisa Mikami
Shimon Sakaguchi
FoxP3-expressing regulatory T cells (Tregs), whether naturally generated in the immune system or unnaturally induced from conventional T cells (Tconvs) in the laboratory, have much therapeutic value in treating immunological diseases and es...
Akshay J Patel,Gary W Middleton
Akshay J Patel
In this review, we explore the biology of the TIGIT checkpoint and its potential as a therapeutic target in lung cancer. We briefly review a highly selected set of clinical trials that have reported or are currently recruiting in non-small ...
Martin Fellermeyer,Consuelo Anzilotti,Christopher Paluch et al.
Martin Fellermeyer et al.
There is an increasing number of immune-checkpoint inhibitors being developed and approved for cancer immunotherapy. Most of the new therapies aim to reactivate tumour-infiltrating T cells, which are responsible for tumour killing. However,...